Company Filing History:

7 out of 33

Leo Pharmaceutical Products, Ltd.

patents

4 out of 38

Leo Pharmaceutical Products Ltd. A/s

patents

3 out of 19

Leo Pharmaceutical Products Ltd. A/s (lovens Kemiske Fabrik

Years Active: 1976-2013

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8455466 - Vitamin d analogues, compositions comprising said analogues and their use (2013-06-04),

2. 7253193 - Cyanoguanidine prodrugs (2007-08-07),

3. 7071178 - Use of vitamin D-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin D3-derivatives (2006-07-04),

4. 6525077 - Cyanoguanidine prodrugs (2003-02-25),

5. 5401731 - Vitamin D analogues (1995-03-28),

6. 5374629 - Vitamin D analogues (1994-12-20),

7. 5206229 - Vitamin D analogues (1993-04-27),

8. 5190935 - Vitamin D analogues (1993-03-02),

9. 5130304 - N-heterocyclic propylidene-1,1-bisphosphonic acids, their production and (1992-07-14),

10. 4870063 - Bisphosphonic acid derivatives, their production and use (1989-09-26),

11. 4866048 - Novel vitamin D analogues (1989-09-12),

12. 4732998 - Bisphosphonic acids and esters (1988-03-22),

13. 4345071 - Derivatives of penicillanic acid (1982-08-17),

14. 4259333 - Cephalosporines (1981-03-31),

15. 4229443 - Derivatives of penicillanic acid (1980-10-21),

Title: Innovations by Ernst T Binderup: Advancements in Medicine

Introduction

Ernst T Binderup is a prominent inventor based in T.ang.strup, Denmark. With a remarkable portfolio of 16 patents, he has made significant contributions to the fields of medicine and pharmaceuticals, particularly in the development of innovative compounds and therapies.

Latest Patents

Among his latest inventions are groundbreaking patents concerning Vitamin D analogues and compositions that incorporate these analogues. These compounds offer a unique chemical structure defined by specific formulas, where R1 and R2 may represent various hydrocarbon groups or halogens. This versatility allows for numerous applications in therapeutic settings, especially in the manufacturing of medicaments. Additionally, his research has led to the creation of pyridyl cyanoguanidine prodrugs, aimed at addressing proliferative diseases such as cancers, showcasing his dedication to advancing medical treatment options.

Career Highlights

Ernst has held positions at notable pharmaceutical companies including Leo Pharmaceutical Products Ltd. and Leo Pharmaceutical Products A/S. His work in these organizations has been pivotal in fostering innovations that enhance patient care through the development of new therapeutic options.

Collaborations

Throughout his career, Ernst T Binderup has collaborated with esteemed colleagues, including Martin John Calverley and Sven Liisberg. These partnerships have facilitated knowledge exchange and the co-development of research initiatives, ultimately leading to successful patent applications and innovations in the pharmaceutical industry.

Conclusion

Ernst T Binderup exemplifies a visionary inventor whose work continues to impact the medical field significantly. Through his numerous patents and collaborations, he has played a crucial role in advancing treatment modalities and improving therapeutic outcomes for patients worldwide. His contributions underscore the importance of innovation in medicine and the ongoing quest for effective solutions in healthcare.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com